Tesamorelin is an analogue of growth hormone-releasing hormone (GHRH), also called growth hormone-releasing factor (GRF). It prompts the body’s own growth-hormone signalling rather than supplying growth hormone. Its best-known trial studied 412 patients with HIV and abdominal fat accumulation over 26 weeks, reporting reduced visceral fat and increased IGF-I in that population — alongside more withdrawals due to adverse events. [Falutz et al., 2007]
How the mechanism is described
It acts on growth-hormone signalling as a releasing-factor analogue rather than being administered growth hormone itself. That distinction matters: the studied pathway is stimulation of the body’s own axis, which is why IGF-I was measured as part of the result. [Falutz et al., 2007]
What the trial measured
The endpoint concerned visceral adipose tissue in a specific clinical population with abdominal fat accumulation. Visceral fat is a particular compartment measured by imaging — not a general body-weight or body-composition claim, and not a statement about people outside that population. [Falutz et al., 2007]
What it is not evidence for
| General fat loss | The population and endpoint were specific; the result does not generalise to healthy adults. |
|---|---|
| Performance or physique use | No such endpoint was studied, so no such claim follows. |
| Canadian authorization | Verify any authorization question in the current Health Canada Drug Product Database record. |
Checklist for reading tesamorelin claims
- Name the population before repeating any result.
- Distinguish visceral fat from overall weight.
- Include withdrawals and adverse events in the summary.
- Check authorization status in the official database rather than inferring it.
Verifying product status
Health Canada’s Drug Product Database lists drug products authorized for sale in Canada, searchable by details such as DIN, name, ingredient or company. Use the specific record; an ingredient match does not transfer authorization to another product. [Health Canada Drug Product Database]
A releasing-factor pathway compared with giving growth hormone directly
Short answer: these are conceptually different points of intervention. Tesamorelin is described as an analogue of growth hormone-releasing hormone (GHRH), also called growth hormone-releasing factor (GRF) — it acts upstream, on the signal. Administering growth hormone itself supplies the hormone directly. The distinction is about pathway position, not about which produces better results.
| Upstream (GHRH / GRF analogue) | Acts on the releasing-factor step. Described in the literature as an analogue of the releasing hormone. |
|---|---|
| Direct hormone administration | Supplies the hormone itself, bypassing that step. |
| What the distinction explains | Why studies of the two are not interchangeable, and why endpoints and populations differ between them. |
| What it does not explain | Any comparative clinical benefit, safety difference, or suitability — none of which is asserted here, because we are not citing a head-to-head study. |
We deliberately stop at the pathway distinction. Extending it into a clinical comparison would require a study that compared them directly, with a stated population and endpoint; we are not citing one, so we make no such comparison. [Falutz et al., 2007]
